Nirma to shell out Rs. 300 Cr. for Core Healthcare acquisition 

FMCG major Nirma is expected to shell out around Rs 300 Crore for the acquisition of Ahmedabad-based Core Healthcare, the largest intravenous (IV) fluids manufacturer in the country. Though a memorandum of understanding to acquire the pharma company was signed three months ago, Nirma has since neither announced the payment details nor the structure of the deal. Nirma has been eyeing the healthcare sector for a while and this would give it a solid platform in the segment.

Health Insurance Market And Third Party Administrators (TPA)

If the business of insuring people's health involves an element of gambling, what plagues this industry's growth is the distrust between hospitals and the middlemen appointed by insurance firms who scrutinize a doctor's decision for repayment. While chiefs of leading hospitals believe the third party administrators (TPAs) appointed by insurance firms to process claims, are too bureaucratic and often delay payments, there is criticism about 'over caring' by doctors leading to inflated bills.

Manipal Edu. And Medical Group (India) Signs MoU with German Company For Hospital Waste Management

Manipal Education and Medical Group (MEMG) has signed a memorandum of understanding (MoU) with Deuttsche Gesellschaft fur Technische Zusammenarbeit (GTZ), Germany, to set up a first of its kind state-of-the-art 'centre of excellence in waste management' at Manipal Hospital, Bangalore. The centre will develop intellectual properties in the field of environment management, while Manipal Academy of Higher Education (MAHE) will offer Diploma courses in the area of environmental and waste management.

Nymox's Alzheimer urine test kit to hit European markets

Nymox Pharmaceutical Corporation has entered into distribution agreements for the marketing and sale of its AlzheimAlert test kit with medical diagnostic companies in Europe.

Apollo Health Signs MoU With SBI For Financing Apollo Clinics Franchises

Apollo Health & Lifestyle (AHLL), a wholly-owned subsidiary of Apollo Hospitals, on Friday said it has signed an MoU with State Bank of India to offer term loans to its franchises. Under the MoU, AHLL will nominate State Bank of India as its preferred financier to its prospective franchises for opening of Apollo clinics throughout India, AHLL said in a release. The MoU was signed between Ratan Jalan, CEO AHLL and J Chandrasekaran, General Manager, SME Business Unit, State Bank of India.

Wockhardt launches automatic insulin delivery devices

Pharmaceutical major Wockhardt Ltd has launched India's first automatic insulin delivery device specially designed for the convenience of Indian diabetic patients.

SIS to consolidate Indian operations

Surgical Information Systems (SIS) to consolidate its Indian operations based at Hyderabad and signs up with new clients globally to be supported from its India development cum support centre.

Vascular Concepts to launch combination drug eluting stent

Bangalore based Vascular Concepts, a leading company engaged in the design, development and manufacture of endovascular medical devices, plans to launch combination drug eluting stent soon. Speaking to Express Pharma Pulse, Swaminathan M Jayaraman, chief executive office, Vascular Concepts, said that the combination drug eluting stent shall enable to target different cells at the same time.

Fresenius to invest Rs 10 crore in Pune Facility 

Fresenius Kabi India Pvt Ltd, a wholly owned subsidiary of Fresenius Kabi AG, Germany, is planning to increase its presence in the country in a big way. The company is in the process of upgrading its manufacturing facility to meet European Union Good Manufacturing Practice (regulatory standards) and expects a 20 per cent growth in its turnover in the next year.

Mexican drug industry delegation visits Indian drug firms 

An 11-member drug industry mission from Mexico, facilitated by Confederation of Indian Industry (CII), is exploring business opportunities in India. The delegation is having interactions with leading domestic companies, research institutions and government departments. 

IVTPL launches latest DES-COSTER for coronary heart disease 

IVTPL (Interventional Technologies Pvt. Ltd.) has launched COSTAR, the latest generation drug eluting stent (DES), to treat Coronary Heart Disease (CHD). COSTAR is a product of ConorMed USA. The product makes use of "Reservoirs" or holes which are made in the stent itself and which houses the drug and the polymer rather than coating the stent surface with the polymer and the drug. This results in overcoming the problems of polymer cracking when the stents have to be implanted in more difficult and tortuous arteries.